Amneal Pharma Resubmits New Drug Application for IPX203 to FDA and Announces Move to Nasdaq; Partners with BIAL for U.S. Licensing Agreement on ONGENTYS
Amneal Pharmaceuticals, Inc. (Amneal), a leading global pharmaceutical company, has recently made significant announcements regarding its drug development, stock market listing, and strategic partnerships. In a press release on February 8, 2024, Amneal announced that it has resubmitted a Complete Response to the U.S. Food and Drug Administration (FDA) for IPX203, a novel oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules used for the treatment of Parkinson’s disease (PD). This resubmission reflects Amneal’s commitment to providing innovative treatment options for patients with neurodegenerative disorders.
The resubmission of IPX203’s New Drug Application (NDA) comes after thorough discussions and feedback from the FDA following its initial review. As part of the resubmission, Amneal has addressed the FDA’s concerns and provided additional information to support the safety, efficacy, and quality of IPX203. The company is hopeful that this resubmission will pave the way for the eventual approval of IPX203 as a new treatment option for PD patients.
In a separate announcement, Amneal revealed its decision to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Stock Market (Nasdaq). This strategic move is expected to occur on December 27, 2023. By joining the Nasdaq Composite Index and Nasdaq Biotechnology Index, Amneal aims to enhance its visibility and positioning within the biopharmaceutical industry. The company believes that this transfer will provide it with increased exposure to a larger investor pool and facilitate better access to capital markets for future growth initiatives.
Furthermore, Amneal has entered into a licensing agreement with BIAL - Portela & Ca. S.A. (BIAL), a renowned Portuguese pharmaceutical company. This agreement grants Amneal exclusive rights to market and distribute BIAL’s ONGENTYS (opicapone) in the United States, starting from December 18, 2023. ONGENTYS is a proprietary once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor indicated for the adjunctive treatment of PD in combination with levodopa/carbidopa. By partnering with BIAL, Amneal expands its portfolio of neurology-focused products and reinforces its commitment to addressing unmet medical needs in the neurodegenerative space.
The collaboration with BIAL aligns with Amneal’s strategic vision to deliver differentiated treatment options to patients and healthcare professionals. The company plans to commence distribution of ONGENTYS in early 2024, thereby broadening its therapeutic offerings for PD management.
In conclusion, Amneal Pharmaceuticals’ recent announcements highlight its dedication to advancing the field of neurology through the resubmission of IPX203’s NDA to the FDA, the move to the Nasdaq Stock Market, and the strategic partnership with BIAL for U.S. licensing of ONGENTYS. These endeavors demonstrate Amneal’s commitment to providing effective and innovative therapeutic options for patients with Parkinson’s disease and other neurological conditions. As these developments unfold, it will be exciting to witness the impact of Amneal’s efforts on improving patient outcomes and shaping the future of neuropharmacology.
Comments